相关实验视频

Updated: Jun 2, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

统计剂与免疫检查点抑制剂的使用以及非小细胞肺癌的存活率

Michael T Marrone¹, Joshua E Reuss², Anna Crawford³

¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.

Clinical lung cancer

|January 16, 2025

概括

与免疫检查点抑制剂 (ICI) 同时使用他类药物可能会降低非小细胞肺癌 (NSCLC) 患者的死亡率. 这项研究发现,在接受ICI治疗的老年NSCLC患者中,他类药物的使用与肺癌特异性和整体死亡率降低的风险有关.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
流行病学流行病学

背景情况:

免疫检查点抑制剂 (ICI) 已经彻底改变了非小细胞肺癌 (NSCLC) 治疗.
类药物是常用的降脂药物,具有潜在的免疫调节作用.
在NSCLC中,他类药物的使用和ICI疗效之间的相互作用仍然不完全理解.

研究的目的:

研究接受ICI治疗的NSCLC患者同时使用他类药物与死亡结果之间的关联.
评估他类药物使用对肺癌特异性和整体死亡率的影响.

主要方法:

在2007-2017年间被诊断患有NSCLC的65岁以上的医疗保险受益人的回顾性分析.
用ICI治疗的患者被确定并对死亡结果进行了跟踪.
考克斯模型使用时间更新的他类药物使用和倾向性得分调整来估计危险比率.

主要成果:

与ICI同时使用他类药物与肺癌特异性死亡率降低41%的风险相关 (HR=0.59).
达丁类药物的使用也与整体死亡率显著降低的风险有关 (HR=0.62).
这些关联在分析PD-1抑制剂和不同类型的他类药物时保持一致.

结论:

与ICI同时使用他类药物似乎与老年NSCLC患者的生存率改善有关.
需要进一步的前性研究和随机试验来证实这些发现.
未来的研究应该探索潜在的机制和最佳的他类药物-ICI组合.

关键词:

死亡率死亡率死亡率年龄较大的成年人.追溯性队列研究追溯性队列研究这就是SER-Medicare.对生存分析的分析.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...